Mathias Schmidt

Dr. Schmidt joined ArmaGen as the chief executive officer, as well as member of ArmaGen’s board of directors, in October 2016. Dr. Schmidt has more than 17 years of global biopharmaceutical industry experience in executive management focused on the research and development of biotherapeutics and pharmaceuticals. Prior to ArmaGen, he held various positions with Takeda Pharmaceuticals and its subsidiaries since 2001, including oncology drug discovery, early alliance management and overseeing biologics. He joined Takeda California in 2012 as Vice President of Biological Sciences where he built a highly functional Biotherapeutics unit serving all therapeutic indications and all research sites within the global Takeda organization. In 2011, he was awarded the venia legendi in pharmacology from the University of Konstanz. He and his team developed a HER-2 specific immunotoxin that subsequently entered the clinic when he studied at the University of Freiburg. After working for several years at various cancer hospitals in Germany and the U.S., he joined the pharmaceutical industry in 1999, where he developed a great passion for drug discovery and development, especially for protein therapeutics.

He holds an M.S. degree in Biotechnology from the University of Stuttgart (Germany) and a Ph.D. in Tumor Biology (summa cum laude) from the University of Freiburg. He studied cellular biology and pharmacology at the University of Constance.